<DOC>
	<DOCNO>NCT00301314</DOCNO>
	<brief_summary>The majority patient Hodgkin Lymphoma ( HL ) cure radiation therapy and/or combination chemotherapy . However , patient relapse attain complete remission chemotherapy primary refractory disease poor outcome conventional chemotherapy regimen . Treatment result standard−dose second−line regimen produce low complete remission rate minimal survival benefit . Single institution study show well outcome autologous stem cell transplant group patient compare historical control receive conventional treatment . In retrospective review , aim analyze outcome determine independent prognostic factor would correlate long−term outcome patient HL receive autologous stem cell transplant past Royal Marsden Hospital Eligible patient ( current−follow−up ) identify transplant database eligible study . Accrual eligible patient currently follow−up perform clinic time next appointment . All patient accrue give informed consent participate study retrospective case note review , discussion study investigator receive study information sheet . The result analysis publish peer−reviewed medical journal .</brief_summary>
	<brief_title>A Retrospective Study Toxicity Outcome High Dose Chemotherapy With Autologous Stem Cell Transplant Patients With Hodgkin Lymphoma ( HL ) .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>) Age 18 b ) Patients Hodgkin Lymphoma receive autologous stem cell transplant c ) Informed write consent ) Medical psychiatric condition compromise patient 's ability give inform consent b ) HIV positive AIDS relate lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>